Erin L Winstanley1, Amanda N Stover2, Judith Feinberg3. 1. Department of Behavioral Medicine and Psychiatry, School of Medicine, West Virginia University, Morgantown, WV, United States of America. Electronic address: erin.winstanley@hsc.wvu.edu. 2. School of Pharmacy, West Virginia University, Morgantown, WV, United States of America. 3. Department of Behavioral Medicine and Psychiatry, School of Medicine, West Virginia University, Morgantown, WV, United States of America.
Abstract
BACKGROUND: Harm reduction services infrequently address alcohol use among clients using opioids, despite the evaluated risk of overdose or medical consequences for clients with viral infections. The purpose of this study is to assess concurrent alcohol and opioid use among syringe services and overdose prevention program participants predominately in southern Ohio and northern Kentucky. METHODS: This is a cross-sectional study using self-report data (n = 1,142) pooled across regional overdose prevention programs and a mobile syringe services program. The outcome variable was concurrent use categorized as no concurrent alcohol, prescription opioid or heroin use; alcohol and heroin or prescription opioid use; and alcohol, prescription opioid and heroin use in the past three months. RESULTS: The sample was predominantly white (95%), 56% were male and the mean age was 33 years old. Forty-seven percent of the clients had no concurrent use of alcohol and opioids; 20.1% reported concurrent use of alcohol and either heroin or prescription opioids; and 33.4% reported concurrent use of alcohol, heroin and prescription opioids in the past 3 months. Lifetime suicidal ideation and non-opioid drug use were associated with concurrent alcohol and opioid use in the multivariable model. CONCLUSION: Harm reduction clients with concurrent alcohol and opioid use may warrant enhanced overdose prevention services. Syringe services and overdose prevention program participants may benefit from education or a brief intervention on alcohol consumption.
BACKGROUND: Harm reduction services infrequently address alcohol use among clients using opioids, despite the evaluated risk of overdose or medical consequences for clients with viral infections. The purpose of this study is to assess concurrent alcohol and opioid use among syringe services and overdose prevention program participants predominately in southern Ohio and northern Kentucky. METHODS: This is a cross-sectional study using self-report data (n = 1,142) pooled across regional overdose prevention programs and a mobile syringe services program. The outcome variable was concurrent use categorized as no concurrent alcohol, prescription opioid or heroin use; alcohol and heroin or prescription opioid use; and alcohol, prescription opioid and heroin use in the past three months. RESULTS: The sample was predominantly white (95%), 56% were male and the mean age was 33 years old. Forty-seven percent of the clients had no concurrent use of alcohol and opioids; 20.1% reported concurrent use of alcohol and either heroin or prescription opioids; and 33.4% reported concurrent use of alcohol, heroin and prescription opioids in the past 3 months. Lifetime suicidal ideation and non-opioid drug use were associated with concurrent alcohol and opioid use in the multivariable model. CONCLUSION: Harm reduction clients with concurrent alcohol and opioid use may warrant enhanced overdose prevention services. Syringe services and overdose prevention program participants may benefit from education or a brief intervention on alcohol consumption.
Authors: Magdalena Cerdá; Julián Santaella; Brandon D L Marshall; June H Kim; Silvia S Martins Journal: J Pediatr Date: 2015-06-06 Impact factor: 4.406
Authors: Jennifer V Campbell; Holly Hagan; Mary H Latka; Richard S Garfein; Elizabeth T Golub; Micaela H Coady; David L Thomas; Steffanie A Strathdee Journal: Drug Alcohol Depend Date: 2005-08-29 Impact factor: 4.492
Authors: Michael D Stein; Anthony Charuvastra; Bradley Anderson; Mindy Sobota; Peter D Friedmanna Journal: Addict Behav Date: 2002 Sep-Oct Impact factor: 3.913
Authors: Anna Hayden; Kanna Hayashi; Huiru Dong; Michael-John Milloy; Thomas Kerr; Julio S G Montaner; Evan Wood Journal: BMC Public Health Date: 2014-11-06 Impact factor: 3.295
Authors: Kristen N Amico; Miranda E Arnold; Morgan S Dourron; Matthew G Solomon; Jesse R Schank Journal: Psychopharmacology (Berl) Date: 2022-08-16 Impact factor: 4.415
Authors: Kevin Y Xu; Ned Presnall; Carrie M Mintz; Jacob T Borodovsky; Nisha R Bhat; Laura J Bierut; Richard A Grucza Journal: JAMA Netw Open Date: 2021-02-01